Actinic Keratosis Pipeline 2025

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

Schedule a 30 minutes session to understand our consulting capabilities – SCHEDULE NOW

Table of Content:

1. Introduction

1.1.Report Overview

2. Actinic Keratosis - Overview

3. Executive Summary

4. Actinic Keratosis : PipelineAssessment

4.1.By Stage of Development

4.2.By Route of Administration

4.3.By Drug Class

4.4.By Molecule Type

4.5.By Therapy Area / Indication

4.6.By Drug Target

4.7.By Sponsor

5. Actinic Keratosis: Company &Drug Profiles

5.1.Clinical Stage

5.1.1. PD P 506 A – photonamic GmbH& Co. KG

5.1.1.1. Company Overview

5.1.1.2. Product Description

5.1.1.3. R&D Status &Development Activities

5.1.1.4. Mechanism of Action

5.1.1.5. Molecule Type

5.1.1.6. Stage of Development

5.1.1.7. Indications

5.1.1.8. Route of Administration

5.1.1.9. Funding

5.1.2. SOR007 – NanOlogy LLC

5.1.2.1. Company Overview

5.1.2.2. Product Description

5.1.2.3. R&D Status &Development Activities

5.1.2.4. Mechanism of Action

5.1.2.5. Molecule Type

5.1.2.6. Stage of Development

5.1.2.7. Indications

5.1.2.8. Route of Administration

5.1.2.9. Funding

5.1.3. A-101 – Aclaris Therapeutics,Inc.

5.1.3.1. Company Overview

5.1.3.2. Product Description

5.1.3.3. R&D Status &Development Activities

5.1.3.4. Mechanism of Action

5.1.3.5. Molecule Type

5.1.3.6. Stage of Development

5.1.3.7. Indications

5.1.3.8. Route of Administration

5.1.3.9. Funding

5.1.4. Others

5.2. Preclinical

5.2.1. Company Overview

5.2.2. Product Description

5.2.3. R&D Status &Development Activities

5.2.4. Mechanism of Action

5.2.5. Molecule Type

5.2.6. Indications

5.2.7. Route of Administration

5.2.8. Funding

6. Actinic Keratosis: An Overview onDormant & Discontinued Pipeline Candidates

6.1.Overview

6.2.Product Description

6.3.Reason for Discontinuation

7. Actinic Keratosis: Additional KeyInsights

7.1.Epidemiology Overview: Actinic Keratosis

7.2.Current Market Scenario: Actinic Keratosis Therapeutics

8. Actinic Keratosis: News, PressReleases and Conference Details

Note:

1) This Table of Content is tentative and subject to change as the research progresses.

2) Please note that the drug candidates included as examples were in the pipeline when this TOC was designed and their status might have changed since then.